M. Buch

发表

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α?

P. Emery, M. Quinn, P. Conaghan, 2004, Annals of the rheumatic diseases.

Comprehensive genetic and functional analysis of FcÎ³Rs in rituximab therapy for autoimmunity reveals a key role for FcÎ³RIIIa on NK cells

J. Barrett, A. Barton, I. Bruce, 2021, medRxiv.

POS0086 ANALYSIS OF DISEASE ACTIVITY MEASURES IN THE CONTEXT OF A METHOTREXATE WITHDRAWAL STUDY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB 11 MG ONCE DAILY + METHOTREXATE: POST HOC ANALYSIS OF DATA FROM ORAL SHIFT

K. Lee, B. Haraoui, R. Fleischmann, 2021, Annals of the Rheumatic Diseases.

Fluorodeoxyglucose positron emission tomography for the diagnosis of giant cell arteritis

P. Emery, S. Bingham, M. Buch, 2004 .

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

A. Radjenovic, P. Emery, G. Firestein, 2008, Annals of the rheumatic diseases.

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

Michael J. Green, D. M. van der Heijde, P. Emery, 2014, Annals of the rheumatic diseases.

of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.

A. Radjenovic, P. Emery, G. Firestein, 2009 .

Buch, M. H. et al. (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging

A. Radjenovic, P. Emery, G. Firestein, 2009 .

Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis

P. Emery, P. Conaghan, S. Proudman, 2009, Annals of the rheumatic diseases.

The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).

P. Emery, J. Isaacs, M. Quinn, 2008, Rheumatology.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

R. Landewé, P. Emery, K. Pavelka, 2010, Annals of the rheumatic diseases.

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis

W. Dixon, A. Barton, I. Bruce, 2015, Arthritis & rheumatology.

POS0237 MAJOR ADVERSE CARDIOVASCULAR EVENTS, MALIGNANCIES AND VENOUS THROMBOEMBOLISM BY BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

Deepak L. Bhatt, M. Dougados, G. Koch, 2022, Annals of the Rheumatic Diseases.

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

D. Furst, P. Emery, A. Wells, 2006, Annals of the rheumatic diseases.

Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level

P. Emery, F. Ponchel, E. Jones, 2009, Annals of the rheumatic diseases.

Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients

P. Emery, M. McDermott, M. Mcdermott, 2012, Clinical and experimental immunology.

POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

Deepak L. Bhatt, M. Dougados, A. Yndestad, 2022, Annals of the Rheumatic Diseases.

OP0264 IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

Deepak L. Bhatt, M. Dougados, G. Koch, 2022, Annals of the Rheumatic Diseases.

A2.42 Clinical utility of measuring naÏve CD4+T-cell in early ra patient to predict remission on mtx: A replication study

P. Emery, F. Ponchel, R. Parmar, 2016 .

SAT0049 21st century state of rheumatoid arthritis management in the uk

P. Emery, A. Bishop-Bailey, M. Buch, 2017 .

Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey

P. Machado, P. Mandl, L. Gossec, 2012, Annals of the Rheumatic Diseases.

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

D. M. van der Heijde, P. Emery, A. Morgan, 2013, Annals of the rheumatic diseases.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

S. Tuck, B. Harrison, B. Griffiths, 2022, Rheumatology.

POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

A. Regierer, J. Askling, D. Aletaha, 2023, Annals of the Rheumatic Diseases.

OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

A. Regierer, J. Askling, D. Aletaha, 2023, Annals of the Rheumatic Diseases.

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

W. Dixon, I. Bruce, Paul Wordsworth, 2013, The Pharmacogenomics Journal.

AB0469 Can Anti-TNF-Induced Autoantibody Conversion be Reversed by Switching to Abatacept Therapy in Patients with RA on Background MTX?

M. Schiff, A. Johnsen, M. Buch, 2015 .

Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.

H. Marzo-Ortega, S. Bingham, M. Buch, 2004, Rheumatology.